Department of Abdominal Surgery and Transplantation, CHU de Liège, University of Liège, 4000 Liege, Belgium.
World J Gastroenterol. 2011 Jul 7;17(25):3069-72. doi: 10.3748/wjg.v17.i25.3069.
Hepatitis B (HBV) reactivation induced by chemotherapy is problem encountered recently in the management of malignant diseases. Chemotherapy-induced HBV reactivation may ultimately lead to terminal acute liver failure. Liver transplantation (LT) currently remains the only definitive treatment option for such cases, but is generally denied to patients suffering from malignancy. Here, the authors describe 2 cases of cancer-free and HBV graft re-infection-free survival after LT performed for terminal liver failure arising from HBV reactivation induced by chemotherapy for advanced stage lymphoma. These 2 cases, and some other reports in the literature, may suggest that patients suffering from hematologic malignancies and terminal liver disease can be considered for LT if the prognosis of their hematologic malignancy is good.
化疗引起的乙型肝炎病毒（HBV）再激活是恶性肿瘤治疗中最近遇到的问题。化疗诱导的 HBV 再激活可能最终导致终末期急性肝衰竭。肝移植（LT）目前仍然是治疗此类病例的唯一确定性治疗选择，但通常不给予患有恶性肿瘤的患者。在这里，作者描述了 2 例因晚期淋巴瘤化疗诱导的 HBV 再激活导致终末期肝衰竭而行 LT 后无癌症和 HBV 移植物再感染的生存病例。这 2 例病例以及文献中的其他一些报道表明，如果血液恶性肿瘤的预后良好，患有血液恶性肿瘤和终末期肝病的患者可以考虑进行 LT。
